Moxifloxacin monotherapy on par with combination therapy in CAP

Once daily moxifloxacin monotherapy is as effective as combination therapy with high-dose levofloxacin plus high-dose ceftriaxone for the treatment of severe community-acquired pneumonia (CAP) requiring hospitalisation, according to results of the multinational MOTIV* study presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [Nice, France; April 2006]. No significant difference in clinical cure rates was observed between the two per protocol treatment groups; the clinical cure rates 4−14 days after the final dose were 86.9% in the moxifloxacin group and 89.9% in the high-dose combination therapy group. Similar clinical cure rates were demonstrated in patients presenting with the most severe (Pneumonia Severity Index [PSI] class IV-V) disease.